Decoy Therapeutics Inc.
DCOY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DCOY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DCOY
Decoy Therapeutics Inc. (DCOY) is a preclinical biopharmaceutical discovery and development company focused on identifying and developing product candidates for viral diseases and colon cancer, with no approved products or commercial revenue to date.
Key risk: Preclinical stage with no revenue
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Decoy Therapeutics Inc..
Decoy Therapeutics Inc. (DCOY) is a preclinical biopharmaceutical discovery and development company focused on identifying and developing product candidates for viral diseases and colon cancer, with no approved products or commercial revenue to date.
- Decoy is a preclinical-stage biopharmaceutical company with no product candidates that have proceeded to clinical trials and no commercial revenue generated [sec · filed 2025-08-22].
- The company plans to bring certain product candidates into early clinical development beginning in the first half of 2026, subject to factors including its ability to raise additional capital [sec · filed 2025-08-22].
- As of June 30, 2026, Decoy reported cash and equivalents of $8.3 million, total revenue of $0.2 million, and a net loss of -$2.4 million [sec].
- Decoy has incurred net losses every year since inception and expects to continue incurring significant losses for the foreseeable future [sec · filed 2025-08-22].
- The company will need to raise substantial additional capital to fund operations and advance its programs, and failure to do so could force it to cease operations [sec · filed 2026-08-04].
What works
- Decoy has identified and is advancing preclinical product candidates targeting specific diseases, including viral diseases and colon cancer, indicating a focused pipeline [sec · filed 2025-08-22].
- The company has structured a Private Placement with milestone-based warrants that could provide additional funding upon achieving clinical milestones, potentially supporting further program advancement [sec · filed 2026-08-04].
What to weigh
- Decoy has no product candidates that have entered clinical trials, no approved products, and has never generated revenue from product sales, with no expectation of commercial revenue for the foreseeable future [sec · filed 2025-08-22].
- The company has incurred net losses every year since inception and faces significant uncertainty in obtaining the additional capital needed to continue operations and advance its pipeline [sec · filed 2025-08-22].
- Decoy's ability to bring product candidates into clinical development depends on factors beyond its control, including its ability to raise funds, and any future financing may be highly dilutive to existing stockholders [sec · filed 2025-08-22].
From the filings
Quoted directly from source documents.
Decoy has no product candidates that have proceeded to clinical trials and no commercial revenue.
“Decoy has no pharmaceutical product candidates that have proceed to clinical trials or generated any commercial revenue, does not expect to generate revenues from the commercial sale of pharmaceutical products for foreseeable future, and may never generate revenues from the sale of pharmaceutical products.”
SEC filings · August 22, 2025
Decoy will need to raise substantial additional capital to fund operations and advance programs.
“As a result, we will need to raise substantial additional capital to fund our operations and advance our programs.”
SEC filings · August 4, 2026
Decoy has incurred net losses every year since inception.
“We have incurred net losses every year since inception.”
SEC filings · August 22, 2025
Risks & what to watch (4)›
Key risks
- Preclinical stage with no revenue — Decoy has no clinical-stage candidates, no approved products, and no commercial revenue; may never generate product revenue [sec · filed 2025-08-22].
- Need for substantial additional capital — The company requires significant funding to continue operations and advance programs; failure to raise capital could force cessation of operations [sec · filed 2026-08-04].
- History of net losses — Decoy has incurred net losses every year since inception and expects to continue incurring losses for the foreseeable future [sec · filed 2025-08-22].
- Dilutive financing risk — Any future financing may be highly dilutive to existing stockholders, and may not be available on acceptable terms [sec · filed 2025-08-22].
What to watch
- Ability to raise additional capital through the Private Placement milestone warrants or other financing sources [sec · filed 2026-08-04].
- Initiation of clinical trials for lead product candidates, planned for first half of 2026 but dependent on funding [sec · filed 2025-08-22].
- Progress of preclinical development for viral disease and colon cancer programs [sec · filed 2025-08-22].
- Cash runway and quarterly financial results, given cash of $8.3M as of June 30, 2026 [sec].
Sources: SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Decoy Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Decoy Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
9.5 months
D/E 1.08 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$7
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 1 | $7 |
Short Interest
as of May 20, 2026- % of float
- 4.4%
- Days to cover
- 0.8
- Shares short
- 23,252
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DCOY short interestGovernance
Frequently asked questions
What is the AI investment thesis for Decoy Therapeutics Inc.?
Decoy Therapeutics Inc. (DCOY) is a preclinical biopharmaceutical discovery and development company focused on identifying and developing product candidates for viral diseases and colon cancer, with no approved products or commercial revenue to date.
What is Decoy Therapeutics Inc.'s lead drug candidate?
Decoy Therapeutics Inc.'s most advanced tracked candidate is cov (Preclinical) for Pan-Coronavirus prophylactic for immunocompromised patients.
Who is the CEO of Decoy Therapeutics Inc.?
Mr. Frederick E. Pierce II is the chief executive officer of Decoy Therapeutics Inc. (DCOY).
Where is Decoy Therapeutics Inc. headquartered?
Decoy Therapeutics Inc. (DCOY) is headquartered in Houston, TX, United States.
What therapeutic areas does Decoy Therapeutics Inc. focus on?
Decoy Therapeutics Inc. develops therapies across Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.